Orifarm, officially known as Orifarm Group, is a prominent player in the pharmaceutical industry, headquartered in Denmark (DK). Founded in 1994, the company has established itself as a leader in the development, production, and distribution of generic medicines and parallel imports, primarily serving the European market. With a strong focus on quality and accessibility, Orifarm offers a diverse portfolio of products, including prescription medications and over-the-counter solutions. Their commitment to innovation and sustainability sets them apart in a competitive landscape. Over the years, Orifarm has achieved significant milestones, including expanding its operational reach across multiple European countries. The company is recognised for its dedication to improving patient access to essential medicines, solidifying its position as a trusted partner in the healthcare sector.
How does Orifarm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Orifarm's score of 38 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Orifarm reported total carbon emissions of approximately 11,949,000 kg CO2e, comprising about 4,420,000 kg CO2e from Scope 1 and about 7,529,000 kg CO2e from Scope 2 emissions. This marks a significant increase from previous years, with total emissions in 2022 recorded at about 12,579,000 kg CO2e. Orifarm has committed to achieving net-zero emissions across all scopes by 2050, as part of its long-term climate strategy. The company is a member of the Business Ambition for 1.5°C initiative, demonstrating its commitment to aligning with global climate goals. Additionally, Orifarm has set near-term targets and is actively working towards reducing its carbon footprint in the pharmaceutical sector. The company’s emissions data reflects its ongoing efforts to monitor and manage its environmental impact, while its long-term commitments indicate a proactive approach to sustainability and climate responsibility.
Access structured emissions data, company-specific emission factors, and source documents
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|
Scope 1 | 732,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Scope 2 | 575,000 | 000,000 | 000,000 | 000,000 | 0,000,000 | 00,000,000 |
Scope 3 | - | - | - | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Orifarm is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.